Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Low-Risk Polycythemia Vera Treated with Phlebotomies: Clinical Characteristics, Hematologic Control and Complications in 358 Patients from the Spanish Registry of Polycythemia Vera

Blood (2021) 138 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2021-145012

Published: 2021

Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2021-147543

Published: 2021

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020

Journal Articles

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

John Mascarenhas, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Regina Garcia-Delgado, MD, Andrzej Pluta, MD, Hope Qamoos, CNP, Anne Uyei, MD, Damaj Gandhi Laurent, MD PhD, Haifa K Al-Ali

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-134262

Published: 2020

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Blood (2013) 122 (21): 2754.

https://doi.org/10.1182/blood.V122.21.2754.2754

Published: 2013

Journal Articles

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Regina Garcia Delgado, Dunia de Miguel, Alicia Bailen, José Ramón Gonzalez, Joan Bargay, Jose F Falantes, MD, Rafael Andreu, Fernando Ramos, Mar Tormo, Rafael F Duarte, MD, PhD, Ma José Jiménez Lorenzo, Salut Brunet, Benet Nomdedeu, Antonio Figueredo, Javier Casaño, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Blood (2012) 120 (21): 1710.

https://doi.org/10.1182/blood.V120.21.1710.1710

Published: 2012

Journal Articles

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Moshe Mittelman, MD, Sarit Assouline, Evangelos Briasoulis, Arancha Alonso, MD, Regina Garcia Delgado, MD, Peter O'Gorman, M.D., Hyeoung Joon Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Andrey Zaritskey, Catherine M. Flynn, MD, MRCP, FRCPath, Yoo-Hong Min, María Diez-Campelo, Alexandr Myasnikov, Frank Mannino, Yasser Mostafa Kamel, Conrad Messam, Nicole L. Stone, PhD, Geoffrey W. Chan, MD

Blood (2012) 120 (21): 3822.

https://doi.org/10.1182/blood.V120.21.3822.3822

Published: 2012

Journal Articles

Clinical Outcome of CML Patients with Philadelphia Chromosome Complex Variants.

Santiago del Castillo, Regina Garcia Delgado, Laura Entrena, Agustin M Hernandez, Arturo Campos, Jose Duarte, Ana I Gallardo, Guacimara Sanchez, Maria Cerda, Gema Ramirez

Blood (2010) 116 (21): 4499.

https://doi.org/10.1182/blood.V116.21.4499.4499

Published: 2010

Journal Articles

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Blood (2009) 114 (22): 2655.

https://doi.org/10.1182/blood.V114.22.2655.2655

Published: 2009

Journal Articles

The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.

Isabel Caparros, Regina Garcia-Delgado, Arturo Campos, Ana Rosell, Ma Paz Queipo de Llano, Santiago de la Torre, Gemma Ramirez, Laura Entrena, Eulogio Conde, MD, PhD, Santiago Del Castillo, MD, PhD

Blood (2009) 114 (22): 1346.

https://doi.org/10.1182/blood.V114.22.1346.1346

Published: 2009

NARROW

Low-Risk Polycythemia Vera Treated with Phlebotomies: Clinical Characteristics, Hematologic Control and Complications in 358 Patients from the Spanish Registry of Polycythemia Vera

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Clinical Outcome of CML Patients with Philadelphia Chromosome Complex Variants.

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only